In the doctor-initiated trial, dopamine neural progenitor cells derived from allogenic iPS cells are administered to patients suffering from Parkinson’s disease. The experimental design has been developed byo Jun TAKAHASHI at CiRA of Kyoto University in collaboration with Dainippon Sumitomo Pharma.

Dainippon Sumitomo Pharma news release, July 31, 2018